Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting

Nyström, Thomas; Holzmann, Martin J.; Eliasson, Björn; Kuhl, Jeanette; Sartipy, Ulrik

doi:10.1016/j.jacc.2015.05.054

Cited by 39 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperglycemia seems to accelerate the atherosclerotic process. 1,7,9,17 Note that individuals with T1DM included in our study have had hyperglycemia (even if they were below target level at inclusion) for 17 years on average. This long duration of hyperglycemia, even if well controlled, appears to be driving the excess risk of coronary artery disease, and it may not be fully compensated for by optimal risk factor control later in life.…”

Section: Discussionmentioning

confidence: 99%

“…For example, complications of coronary artery disease predominate outcomes in patients with T1DM, 1,7,17 and high-dose statin treatment is both safe and effective in reducing the risk of coronary artery disease. Moreover, use of an insulin pump is a proven means to improve glycemic control and may reduce the risk of cardiovascular outcomes (including heart failure), which is why it should be considered early in the management of T1DM.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Range of Risk Factor Levels

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Range of Risk Factor Levels

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…We used the NDR, which has been described previously 3,18,19 and includes most individuals in Sweden with T1D; it correlates at approximately 96% with the clinical definition of T1D. The epidemiological definition of T1D in the NDR is onset of diabetes before 30 years of age and treatment with insulin only.…”

Section: Data Sources and Patient Populationmentioning

confidence: 99%

Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes

Nyström

Holzmann

Eliasson

et al. 2017

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…The needs of the people with type 1 diabetes are different from those of the majority of people with diabetes and have to be addressed separately. In patients with T1DM, poor glycaemic control before CABG was associated with increased long-term risk of death or MACE [14].…”

Section: Discussionmentioning

confidence: 96%

Fasting C-Peptide Response, and Its Clinical Impact in Type I Diabetics to a Novel Metaphysical Energy Healing Therapy—Preliminary Experience and Observations

Krishnaswami

Ramesh

Krishnaswami

et al. 2016

JDM

View full text Add to dashboard Cite

Type 1 diabetes is classically the true form of insulinopaenic diabetes usually occurring in young children below the age of 15 years and occasionally up to 20 years and characterised by very low/ negligible fasting C-peptide in their blood due to extensive irreversible Beta cell damage. T1DM probably accounts for 5% to 10% of all diagnosed diabetes. The worldwide prevalence of T1DM is 0.1% to 0.3%, with 78,000 new cases every year, especially among young individuals (<5 years). According to BMC Public Health publication in 2015 T1D incidence was larger in males than in females in those aged >15. Type I diabetes is very much lower (20 times) in countries like Japan and India, than the western countries. The European Nicotinamide Diabetes Intervention Trial (ENDIT) is focused on the use of nicotinamide in the prevention of diabetes. In high doses (nicotinamide), it may cause a degree of sedation, a feeling of depression, and in very large dosages, liver toxicity. Because the vitamin cannot be marketed as a drug, the study is not getting a great deal of support from pharmaceutical companies. GAD antibodies (GADA) are a major diagnostic marker for Type 1 diabetes. Phase II clinical trials of a vaccine containing alum and recombinant GAD65, an auto antigen involved in type 1 diabetes, were promising, as of 2014 Phase III trial had failed. In our quest for improving the clinical condition & quality of life of type I DM & also to reduce the economic burden on them, we have embarked on a novel metaphysical energy therapy which we have been trying for the past 3 years at our research Centre. We have so far treated some 15 cases with this DAMM therapy. Among the 15 cases, 6 cases have shown significant improvement in fasting C-peptide levels. With the advent of this new modality of treatment (DAMM Therapy) the cost of treatment will be greatly reduced. This DAMM Therapy apparently has no side effects. This mode * Corresponding author.

show abstract

Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting

Abstract: In patients with T1DM, poor glycemic control before CABG was associated with increased long-term risk of death or MACE. (HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery [HARTROCS]; NCT02276950).

Cited by 39 publications

References 42 publications

Range of Risk Factor Levels

Range of Risk Factor Levels

Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes

Fasting C-Peptide Response, and Its Clinical Impact in Type I Diabetics to a Novel Metaphysical Energy Healing Therapy—Preliminary Experience and Observations

Contact Info

Product

Resources

About